According to Alnylam Pharmaceuticals 's latest financial reports and stock price the company's current Operating Margin is -108.63%. At the end of 2022 the company had an Operating Margin of -108.63%.
Year | Operating Margin | Change |
---|---|---|
2022 | -108.63% | 7.63% |
2021 | -100.93% | -41.86% |
2020 | -173.60% | -56.91% |
2019 | -402.85% | -60.33% |
2018 | -1,015.48% | 86% |
2017 | -545.95% | -37.22% |
2016 | -869.63% | 23.21% |
2015 | -705.83% | -10.92% |
2014 | -792.32% | 306.56% |
2013 | -194.88% | 11.54% |
2012 | -174.73% | 150.82% |
2011 | -69.66% | 62.06% |
2010 | -42.98% | -8.07% |
2009 | -46.76% | 76.12% |
2008 | -26.55% | -83.16% |
2007 | -157.61% | 7.45% |
2006 | -146.68% | -80.71% |
2005 | -760.53% | 0.84% |
2004 | -754.18% | -93.51% |
2003 | -11,618.18% |
Company | Operating Margin | Operating Margin differencediff. | Country |
---|---|---|---|
Novartis NVS | 17.27% | -115.90% | ๐จ๐ญ Switzerland |
Sanofi SNY | 18.21% | -116.76% | ๐ซ๐ท France |
Regeneron Pharmaceuticals REGN | 37.68% | -134.69% | ๐บ๐ธ USA |
Sarepta Therapeutics
SRPT | -88.19% | -18.82% | ๐บ๐ธ USA |
Regulus Therapeutics RGLS | -119.48% | 9.99% | ๐บ๐ธ USA |
OPKO Health
OPK | -36.36% | -66.53% | ๐บ๐ธ USA |
Teva Pharmaceutical Industries TEVA | -20.53% | -81.10% | ๐ฎ๐ฑ Israel |
Arrowhead Pharmaceuticals
ARWR | -71.00% | -34.64% | ๐บ๐ธ USA |
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.